The size of the Liver Cancer Therapeutics Market in Europe was worth USD 170.21 million in 2019 and estimated to be growing at a CAGR of 8.89%, to reach USD 260.57 million by 2024.
Europe's lung cancer diagnostics and therapeutics market will continue to avail favorable growth over the next few years. Invention and new product launches by the current as well as the new market players is the key factor projected to drive this market.
Studies on liver cancer therapeutics illustrate that the prevalence of liver cancer is greater in men than in women and is generally seen in people over the age of 50. Treatment is based on tumor size, location, and overall health. A most common type of liver cancer HCC is often unresectable, meaning that it cannot be removed surgically.
Factors such as increasing elderly population across the region, growing population base of cancer patients, technological developments in treatment and diagnosis procedures, rising number of hospitals and surgical centers and growing demand for minimally invasive cancer treatment techniques are driving the growth of the liver cancer therapeutics market.
However, the high cost involved in the diagnosis, as well as treatment procedures of cancer, is acting as a major restraint for the market.
This research report segmented and sub-segmented into the following categories:
On the basis of therapeutics, the Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.
Regionally, the U.K and Germany are estimated to be the leading markets in this region while France is anticipated to witness the highest growth in the forecast period.
Key players operating in the Europe Liver Cancer Therapeutics Market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Primary
5.1.2 Secondary
5.1.3 Benign Liver growths
5.2 By Therapeutics
5.2.1 Hepatocellular Carcinoma
5.2.2 Cholangio carcinoma
5.2.3 Hepatoblastoma
5.2.4 Targeted Therapy
5.3 By End-Users
5.3.1 Pediatrics
5.3.2 Adults
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Alnylam Pharmaceuticals Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 ImClone Systems Inc.
9.3 Onyx Pharmaceuticals Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Pfizer Inc.
9.6 ArQule Inc.
9.7 Jennerex Biotherapeutics Inc.
9.8 Celsion Corp.
9.9 Bayer Schering Pharma AG
9.10 4SC AG
9.11 Bristol-Myers Squibb Company
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
